Valuing Pharma & Life Sciences
Drug discovery is capital-intensive, uncertain, and time-bound. How do we price innovation that might take a decade to pay off?
Key Drivers
Patent Life & Exclusivity – Determines DCF horizon.
R&D Pipeline – Probability-weighted outcomes matter.
Regulatory Approval – FDA/EMA timelines shape value.
Approaches
Probability-Adjusted DCF – Based on success rates by phase.
Option Pricing – Valuing potential molecule success.
Market Comparables – Benchmarking biotech peers.
Way Forward:
Blend science with finance.
Recognize IP as core asset.
Integrate ESG and social impact metrics.
Should R&D be expensed or capitalized? The debate continues.
pharmaValuation #LifeSciences #IntangibleAssets #BusinessValuation
Absolutely. We have IBBI-Registered Valuers under all three categories—Land & Building, Plant & Machinery, and Securities/Financial Assets. Our team also includes experienced chartered accountants and engineers.
Yes. We offer remote/desk-based valuation for startups, financial assets, and select use-cases. For physical assets, we usually require on-site verification.
Yes. Client confidentiality is paramount. All data shared is stored securely and not disclosed to any third party without your consent.